Verastem names Daniel Paterson COO
This article was originally published in Scrip
Executive Summary
Verastem, a company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, has appointed Daniel Paterson, current chief business officer, to the role of chief operating officer. Mr Paterson has been at Verastem since 2012, initially joining the company as a consultant. Prior to working at Verastem, he was COO of On-Q-ity following its acquisition of The DNA Repair Company where he was the CEO and president from 2006.
You may also be interested in...
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.